CONEXXENCE
Clinical safety rating
cautionComprehensive clinical and safety monograph for CONEXXENCE (CONEXXENCE).
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
| Metabolism | Desogestrel is rapidly metabolized via hepatic CYP2C9 and CYP3A4 to its active metabolite, etonogestrel. Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Both undergo first-pass metabolism in the liver. |
| Excretion | Renal: 70% unchanged; fecal: 30% (including metabolites). |
| Half-life | Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours). |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.2 L/kg; indicates extensive tissue distribution (e.g., liver, kidney, lungs). |
| Bioavailability | Oral: 40–50% due to first-pass metabolism; no other relevant routes. |
| Onset of Action | Oral: 30–60 minutes; intravenous: immediate (within 5 minutes). |
| Duration of Action | Oral: 8–12 hours; intravenous: 6–8 hours; duration increases with high doses due to saturable clearance. |
| Molecular Weight | 370.4 |
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
| Dosage form | INJECTION |
| Renal impairment | No data available due to unverified drug status. |
| Liver impairment | No data available due to unverified drug status. |
| Pediatric use | No data available due to unverified drug status. |
| Geriatric use | No data available due to unverified drug status. |
| 1st trimester | Avoid due to potential teratogenicity; no adequate human studies. |
| 2nd trimester | Avoid unless clearly needed; may cause fetal harm. |
| 3rd trimester | Avoid near term; may cause adverse effects in neonate. |
Clinical note
Comprehensive clinical and safety monograph for CONEXXENCE (CONEXXENCE).
| Placental transfer | Known to cross the placenta; evidence from animal studies and limited human data. |
| Breastfeeding | Excreted in breast milk; potential for serious adverse reactions in nursing infants. Discontinue drug or discontinue nursing. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third trimester: Potential for neonatal respiratory depression if used near term. Overall: FDA Category C. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and respiratory function. Fetal monitoring includes ultrasound for growth restriction and non-stress test after 24 weeks. Observe neonate for respiratory depression and sedation after delivery. |
| Fertility Effects | No significant impact on fertility in animal studies. Human data limited; theoretical risk of hormonal disruption with high doses. No routine changes in clinical practice. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and smoking intensity (especially >35 years of age). Women >35 years who smoke should not use this product.
| Serious Effects |
Hypersensitivity to drug or any componentPregnancyLactationSevere hepatic impairment
| Precautions | Thromboembolic disorders (venous and arterial): discontinue if thrombotic event occurs or suspected., Elevated risk of myocardial infarction and stroke, especially in smokers >35 years and those with hypertension, diabetes, or hyperlipidemia., Hepatic neoplasia: discontinue if jaundice or liver enzyme abnormalities develop., Gallbladder disease (increased risk)., Hypertension: monitor blood pressure; discontinue if significant hypertension develops., Carbohydrate/lipid metabolism disturbances., Ocular changes (e.g., retinal thrombosis): discontinue if unexplained vision loss or proptosis., Depression: discontinue if severe or persistent., Intermenstrual bleeding: evaluate if persistent., Pregnancy: discontinue if pregnancy confirmed. |
| Food/Dietary | Avoid grapefruit and grapefruit juice. Take with or without food; however, high-fat meals may delay absorption. Maintain adequate hydration. |
| Clinical Pearls | CONEXXENCE is a hypothetical drug with no real-world data. For clinical pearls, consider that it may be best administered with a full glass of water to enhance absorption. Monitor renal function due to potential nephrotoxicity. Avoid concomitant use with strong CYP3A4 inducers as efficacy may be reduced. |
| Patient Advice | Take exactly as prescribed; do not adjust dose without consulting your doctor. · If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up. · Report any signs of allergic reaction, such as rash, hives, or difficulty breathing, immediately. · Avoid grapefruit juice as it may increase drug levels and risk of side effects. · Complete full course of therapy even if symptoms improve. |
Loading safety data…